30 closest matches · ranked by relevance
Large B Cell Lymphoma
Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Diffuse Large B-cell Lymphoma
Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Lymphoma
Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years
Lymphoma
Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants
Lymphoma
Primary: Event-free Survival After 12 Months — 78 percentage of participants
Lymphoma
Primary: Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response) — 0.48 proportion of participants
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…
Contiguous Stage II Adult Diffuse Large Cell Lymphoma · Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma · Stage III Adult Diffuse Large Cell Lymphoma
Primary: Progression-free Survival at 1 Year — 77 percentage of participants
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants
Lymphoma
Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants
Composite Lymphoma · Grade 3b Follicular Lymphoma · Stage I Diffuse Large B-Cell Lymphoma
Primary: Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 13…
Lymphoma
Primary: Percentage of Participants With Administration-Associated Reactions (AAR) — 4.2; 8.1; 6.3; 0 Percentage of Participants
Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate — 2; 0 Patients
Lymphoma
Primary: Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration — 36.2; 32 percentage of change in maximum SUV
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Primary: Number of Participants Who Achieved a Complete Response — 47 Participants
Ann Arbor Stage II Grade 1 Follicular Lymphoma · Ann Arbor Stage II Grade 2 Follicular Lymphoma · Ann Arbor Stage III Grade 1 Follicular Lymphoma
Primary: Progression Free Survival — 70.7 months
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Lymphoma
Primary: Overall Response Rate — 53.3; 76.1 percentage of participants — p=0.29